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Recent infectious outbreaks highlight the need for platform technologies that can be quickly deployed 
to develop therapeutics needed to contain the outbreak. We present a simple concept for rapid 
development of new antimicrobials. The goal was to produce in as little as one week thousands of doses 
of an intervention for a new pathogen. We tested the feasibility of a system based on antimicrobial 
synbodies. The system involves creating an array of 100 peptides that have been selected for broad 
capability to bind and/or kill viruses and bacteria. The peptides are pre-screened for low cell toxicity 
prior to large scale synthesis. Any pathogen is then assayed on the chip to find peptides that bind or kill 
it. Peptides are combined in pairs as synbodies and further screened for activity and toxicity. The lead 
synbody can be quickly produced in large scale, with completion of the entire process in one week.
There is wide recognition of the need for the development of new antibiotics1–3. Historically, there has never been 
a wide selection of effective antivirals, with only antivirals for human immunodeficiency virus4, hepatitis B5, 
hepatitis C6, influenza7, herpes and cytomegalovirus8 available in the clinic. The deficiencies in the development 
pipeline have been magnified in outbreaks of new pathogens, such as for Severe Acute Respiratory Syndrome 
(SARS) and Middle East respiratory syndrome (MERS) caused by coronaviruses9, or the wider emergence of a 
known pathogen, such as the Ebola outbreak in West Africa10–12 and Zika virus in the Americas13. Particularly in 
the case of an emergency, it would be ideal to have a standard, ready-to-run platform for developing thousands 
of doses of a new antibiotic or antiviral against the emergent agent in a short time. If the new agents had a high 
probability of low toxicity and high efficacy it would decrease the time to their use in the emergency. Here we 
present a concept for developing antibiotics or antivirals in a systematic, potentially rapid manner based on the 
synbody technology and test its feasibility.
In designing a fast response system, we applied the following requirements. We assumed the infecting agent is 
isolated and available. It may not be required for it to be alive, relieving the necessity for high-level containment. 
We required that the creation of the therapeutic agent could be accomplished in 1 week or less with at least 1,000 
doses produced. The production would integrate simultaneous toxicity screening to increase the probability of 
an approved therapeutic. We did not require that the antibiotic or antiviral be orally available as in an emergency 
intravenous administration may be adequate.
We used the synbody technology14–21 as the starting point for developing a platform to meet these specifica-
tions. Synbodies are bivalent peptides with antibody like features that are chemically synthesized. Two peptides 
that bind different regions of a chosen target, usually with low affinity and specificity, are linked to create a high 
affinity, high specificity reagent. The two arms of the synbody are chosen from a premade set of 10,000 peptides 
from random sequence space that are arrayed on slides. We felt the modular aspect of the synbodies might lend 
them to rapid production, particularly for a large number of doses in a short time. Additionally, the surface of 
viral and bacterial pathogens present repeating binding elements providing additional avidity between bivalent 
synbodies and targets on the surface of pathogens. Below we detail the concept and test the feasibility of its fea-
tures to produce antibiotics and antivirals.
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Results
System overview. We have shown that bacteria18 and viruses20 can be applied to peptide microarrays to gen-
erate synbodies with antibiotic or antiviral activity. The challenge was to create a system to generate the synbodies 
quickly and provide sufficient quantities of the chosen synbody for in vivo testing. The key issue was that the pub-
lished process involved applying the bacterial target to 10,000 peptide microarrays (10 K), choosing and testing 
target peptides, synthesis of large amounts of two or more candidate peptides, synthesis of synbodies and retest-
ing. This process usually takes several months, with the rate-limiting step the synthesis and purification of large 
amounts of the candidate peptides. Our solution to this time issue was to pre-screen a large number of pathogens 
on the 10 K peptide microarray to arrive at 100 peptides that would offer sufficient diversity that any pathogen 
screened would bind two or more of peptides (Fig. 1A). By selecting peptides that are somewhat pathogen specific 
and others that are more broadly reactive, we should be able to select a reduced set of peptides with the potential 
to bind any new pathogen screened against these 100 peptides. It would then be practical to synthesize large 
stocks of these 100 peptides in advance so that 1,000 or more doses of a therapeutic could be produced quickly. 
Once the 100-peptide microarray was developed and the stocks synthesized it would be the starting point for the 
development of any therapeutic. As shown in Fig. 1B, a pathogen is incubated with the 100-peptide microarray 
and peptides binding it identified. These peptides are linked in all combinations to create lead synbodies, using 
the peptide and linker stocks. These leads are screened for activity against the target, preferably in blocking activ-
ity in an in vitro assay. Candidate synbodies are produced in large amounts, purified and tested in mice for acute 
toxicity and on red blood cells for hemolysis. The goal is to integrate the component steps so the whole process 
could be completed in 1 week.
Creating the 100-peptide microarray. To create the 100-peptide library that could potentially bind any 
pathogen, we screened 21 different viruses and bacteria, representing a wide range of pathogenic bacteria and 
viruses on a peptide microarray (Supplementary Table S1). The 10 K array consists of 10,000 peptides spotted 
in duplicate on a standard size glass microscope slide with each peptide composed of 17 variable amino acids 
and an N-terminal CSG- constant region used for immobilization to the surface22. The slide surface is coated 
with a polymer to increase the peptide density and to reduce non-specific binding18. The peptide of each feature 
Figure 1. Development of pathogen binding 100-peptide microarray and rapid synbody discovery system. 
(A) A range of pathogens (10 viruses and 11 bacteria) were screened against a library of 10,000 peptides to 
identify shared and specific pathogen binding peptides. A total of 275 peptides were selected for secondary 
binding screening and down-selected for cellular toxicity. Peptides with confirmed binding and minimal 
toxicity were selected for inclusion into the pathogen binding peptide microarray. (B) Workflow for discovery 
of antimicrobial synbodies. A new or unknown pathogen is fluorescently labeled and screened against the 
pathogen binding 100-peptide microarray. Peptides that bind the pathogen are selected and conjugated to a 
synbody scaffold to produce a synbody library for activity and toxicity testing in a series of in vitro functional 
assays to select antimicrobial synbodies for additional development. IC stain: Intracellular staining; CW stain: 
Cell wall staining.
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is of known sequence and the variable amino acid positions in the peptide are composed of 18 different amino 
acids with a slight for amino acids with aromatic side chains (Supplementary Fig. S1). The bacteria in the panel 
were screened for binding peptides in one of two ways. Live bacteria were screened using a previously published 
method18 while inactivated bacteria were detected using antibodies that were specific to that pathogen. In the live 
bacteria screening assay, the target is labeled with an amine-reactive dye, AlexaFluor (AF), and an internalizing 
dye, Cell Tracker Orange (CTO), and peptides that bind the bacteria without perturbing the membrane produce 
fluorescence in both channels while those that disrupt the membrane only produce fluorescence in the AF chan-
nel. Viruses were screened by detecting binding to a peptide using a fluorescently labeled virus-specific antibody, 
or in some cases directly labeling the virus with an Alexa Fluor dye20. Antibody detection was favored as it avoids 
the problems of the dye interfering with virus binding or binding the peptide itself. The microarray data was 
analyzed and binding peptides were selected according to the following criteria: (i) for pathogens detected via 
antibody, peptides with signals 1.5x higher the antibody only control; (ii) for direct labeled pathogens, peptides 
with signals 2x the background; or for live bacteria, peptides with AF/CTO <5. This selection strategy yielded a 
total of 893 peptides (Fig. 2).
A heat map of the data demonstrates that there are peptides that bind a single organism while there are those 
that bind multiple pathogens (Fig. 2A, Supplementary Information). Some organisms had relatively few peptide 
hits, while others such as E. coli O157:H7 had over 150 peptides that passed the selection criteria (Fig. 2B). The 
majority of peptides bound 1 pathogen, while 127 peptides bound more than 1 pathogen (Fig. 2C). From this 
data set, we selected the 127 multi-pathogen peptides and 161 single pathogen binding peptides for a total of 288 
Figure 2. Bacterial and viral screening against 10,000 peptide microarrays identifies common and specific 
pathogen binding peptides. (A) Heat map of peptides (x-axis) that bound pathogens (y-axis). Positives peptides 
were defined as those with median normalized signal >2x background or >1.5x higher than the detection 
antibody control. For bacteria screened with the IC and CW labeling assay, positive peptides were positive in 
both fluorescent channels with a CW/IC ratio <5 (non-lytic peptides). Peptide intensities are colored in blue for 
negative and red for positive. (B) Total number of peptides positive for each pathogen evaluated. (C) Graphical 
representation of the number of common peptides shared amongst pathogens.
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peptides that could maximally cover the pathogen space. These peptides were then synthesized in three 96-well 
plates and screened in secondary assays for binding and toxicity.
The 288 peptides were synthesized on the 5 mg scale with an N-terminal biotin and used without purification 
(Supplementary Information). When the library quality was analyzed by mass spectrometry, a small number of 
peptides (13 peptides) did not contain the full-length peptide at high abundance when analyzed by mass spec-
trometry and were not included in subsequent assays, reducing the library size to 275 peptides. The first issue was 
to confirm that the peptides bound the target pathogen previously used for selection.
Pathogen binding. Peptides must function when immobilized on a microarray, therefore we printed the 275 
peptide candidates as a new microarray using the same methods as for the 10 K array. We then screened the 10 
viruses and 11 bacteria (Supplementary Table S1) that had been previously tested on the 10 K array to verify bind-
ing to the appropriate pathogen. To increase confidence in the binding data, we changed the detection method for 
several bacterial pathogens, from AF-633/CTO labeling used in the 10 K array experiments to a dual membrane 
labeling approach using AF555 / AF647. Peptides that bound in both array detection methods were consid-
ered true hits. From this analysis, we found that 175 peptides showed binding for 1 or more pathogens (Fig. 3A, 
Supplementary Information).
Each peptide was then tested in an ELISA assay to determine its relative affinity for four different patho-
gens: vaccinia virus, H1N1 influenza virus, and Gram-negative pathogens F. tularensis, and R. prowazekii. 
Representative results from peptides binding to each pathogen are presented in Fig. 3B (Supplementary Fig. S2). 
As can be seen, some peptides showed high binding across all pathogens and all tested concentrations, indicat-
ing likely promiscuous or non-specific binding. However, other peptides had concentration dependent changes 
in pathogen binding. While absolute KD values could not be determined with this method as unpurified pep-
tides were used, relative KD values could be estimated, with many peptides exhibiting concentration dependent 
Figure 3. Secondary screening and evaluation of peptides for inclusion in the pathogen binding 100-peptide 
microarray. (A) Heat map of pathogens screened against 275 peptide array. Each pathogen was labeled with 
AF555 and AF647 and incubated on the array. (B) Representative binding curves from secondary screening 
of 275 peptide library by ELISA. 96-well plates were coated with Vaccinia virus (blue squares), A/PR/8/34 
H1N1(black circles), F. tularensis (green diamonds), or R. prowazekii Madrid (red triangles) and each peptide 
was incubated at the indicated concentrations. (C) In vitro cytotoxicity screen of peptide library. HEK293 cells 
(1 × 106 cells) were incubated for 1 hour with 25 µM of each peptide in replicate wells. Few peptides decreased 
cell viability >10% (dotted line).
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binding. Peptides of this phenotype were classified as probable pathogen binders while non-specific binding or 
non-binding peptides were rejected. A total of 118 peptides passed this screening. In parallel with the binding 
assays, peptides were screened in an in vitro cytotoxicity assay using HEK293 cells. Peptides were screened at 0.25, 
2.5 and 25 μM and the cell viability at 25 μM was plotted (Fig. 3C). Few peptides exhibited toxicity above the assay 
noise and those peptides with the highest toxicity were rejected. Based on these data the peptides were ranked by: 
(1) 275-peptide array binding (2) binding to 1 or more pathogens in ELISA and (3) by in vitro cytotoxicity. A total 
of 82 peptides showed binding in both binding assays and an additional 18 peptides showed binding in the pep-
tide array only. Analysis of the peptides showed that there was a wide distribution of net charges and isoelectric 
points (Supplementary Fig. S3). Only 66% of this library is cationic in contrast to peptides in the antimicrobial 
peptide (AMP) database of which ~82% are cationic23. The 100 peptides were synthesized commercially (Sigma) 
at the 2-gram scale and purified to >95% purity (Supplementary Table S2). This stock was the source of peptides 
for printing 100 peptide arrays and for the synthesis of the synbodies.
To confirm that an unknown pathogen would bind to peptides from this reduced library, we screened two 
pathogens that were not used as part of the peptide selection process, adenovirus and rotavirus. Adenovirus is 
a non-enveloped, double-stranded DNA virus while rotavirus is a non-enveloped, double-stranded RNA virus. 
Each virus was labeled with AF555 and AF647 and tested using the same procedures as before. When the fluo-
rescent signal across both channels is compared, it can be seen that multiple peptides bound each new pathogen 
(Fig. 4). There was correlation between both fluorescent dyes and binding peptides for a new pathogen could be 
easily identified. For example, peptides with relative fluorescence values >10,000 for both fluorophores could 
be selected as binding peptides for the new virus. In this way, multiple peptides could be selected for synbody 
construction. These data indicate that this array can potentially identify binding peptides for any given pathogen.
Rapid Synbody Discovery. The creation of the 100-peptide microarray allowed implementation of the 
selection process. As shown in Fig. 1B, a pathogen of interest is applied to the microarray and peptides selected 
based on the relative florescence. Seven to 10 peptides are selected and the 100 peptide stock used to synthesize 
all combinations of the peptides into synbodies. We developed a modular and combinatorial approach using 
maleimide-thiol conjugation to rapidly produce synbody libraries19–21 where selected peptides are conjugated 
to different peptide scaffolds, each with two conjugation sites, in a combinatorial manner and in parallel. With 
this approach, dozens or even hundreds of synbodies can be produced in a day. The synbodies are evaluated for 
their potency, efficacy, and toxicity with the best selected for production in large scale. Once the synbodies are 
produced they can be screened for pathogen binding by ELISA, in vitro activity in either growth inhibition assays 
for antibacterial or in plaque reduction assays for antiviral synbodies, red blood cell toxicity and kidney toxic-
ity. Candidates that have high target binding, in vitro activity and low toxicity are then prepared on large scale 
(>100 mg) with the same chemistry and purified by HPLC. Parallel primary screening, rapid synbody production 
using stocks of pre-made peptides, and parallel activity and toxicity testing enable this system to produce synbod-
ies candidates in a very rapid fashion.
Once the basic component steps had been optimized a test run for a specific pathogen was executed to 
determine the time to complete synbody production. We chose A/CA/07/2009 H1N1 influenza, a major health 
concern worldwide as a viral test and S. epidermidis, which causes surgery related infections and is a source of 
antibiotic resistance genes, as a bacterial target.
Development of an Antiviral. To test in principal whether an antiviral synbody could be produced by this 
protocol, we focused on development of a viral infection inhibitor for pandemic influenza (A/CA/07/2009 pdm09 
H1N1). We screened H1N1 pdm09 on the 100-peptide array using the two color fluorescent labeling strategy. 
Based on the relative binding to pdm09 we selected 10 peptides (Fig. 5B) and tested these for the ability to bind 
hemagglutinin (HA) and inhibit hemagglutination by pdm09 of red blood cells with different concentrations 
Figure 4. Evaluation of performance of the pathogen binding 100-peptide microarray. (A) Scatterplot of 
adenovirus binding to the 100-peptide microarray detected via AF555 (x-axis) or AF647 (y-axis). The data 
for each point is the average RFU across replicate peptide spots and microarrays. (B) Scatterplot of rotavirus 
binding to the 100-peptide microarray detected via AF555 or AF647.
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(50 µM to 1.76 µM). Peptides p227, p149, and p125 inhibited hemagglutination. While p151, p204, p174, p228, 
p43, p107, and p58 bound A/CA/07/2009 on the peptide array, they did not prevent hemagglutination even 
in higher concentrations (50 µM) (data not shown). Based on HAI screening, peptides p227, p149, and p125 
were used to prepare synbodies through pairwise conjugation to a previously developed synbody scaffold, Sc220. 
Each synbody was hydrolyzed to prevent thiol-exchange reactions that occur when maleimide conjugated pep-
tides are exposed to excess thiols, such as in albumin19. Synbodies were tested in the HAI assay and p227-p227, 
p125-p149, p125-p125, and p149-p149 each exhibited inhibition at 0.781 µM (Fig. 5B). Finally, to test if the syn-
bodies prevented viral cell entry, synbodies p125-p125, p227-p227, p125-p149, and a negative control synbody 
p151-p151, were tested in a plaque reduction assay (Fig. 5C). Cells treated with the neutralizing antibody had 
100% inhibition while the synbodies exhibited a concentration dependent decrease in plaque formation. The IC50 
for p227-p227, p125-p149, and p125-p125 were 0.45 µM, 0.34 µM, and 0.31 µM respectively. These synbodies 
were then tested for hemolysis at 125 µM, a concentration roughly 100 times the IC50, and exhibited less than 10% 
hemolysis (Supplementary Fig. S4) indicating low red blood cell toxicity. These data indicate that a new virus can 
be screened against the small peptide library to discover binding peptides that can be converted into neutralizing 
synbodies in a rapid manner.
Development of an Antibiotic. The data presented above indicates that it is feasible to develop a substan-
tial amount of a synbody anti-viral in one week. We then used the same system to produce a synbody with activity 
against a bacterium, S. epidermidis. While S. epidermidis is from the same genus as S. aureus used in the primary 
selection assay, there are large phenotypic differences between S. epidermidis and S. aureus as well as considerable 
intra strain variation24. As the peptides that were selected for the prototype 100 peptide microarray were designed 
to broadly bind pathogens rather than kill a specific bacteria, we used our previously demonstrated strategy of 
using a binding peptide conjugated to a killing peptide18 to produce synbodies for the proof-of-principle study. 
S. epidermidis was screened against the peptide array and 20 peptides selectively bound S. epidermidis but were 
predicted to have low killing activity based upon their AF/CTO ratio (Fig. 6A). These peptides were tested by MIC 
and they did not inhibit S. epidermidis growth at 50 uM (not shown). Therefore, we selected two positives binders 
(p52 and p104) and one negative control peptide (p42) and conjugated to an S. aureus lytic peptide19, called Ly, to 
produce a small synbody library that was then tested for inhibitory activity. We found that synbodies p42-Ly did 
not inhibit S. epidermidis growth at 50 uM, as expected, while p107-Ly, and p104-Ly inhibited bacterial growth 
with MICs of 12.5 µM, and 6.25 µM, respectively (Fig. 6B). Synbodies were then tested for hemolysis at 125 uM 
and no hemolysis was observed (Supplementary Fig. S3). These data indicate that the synbody system can also be 
used to quickly produce antibacterial candidates for additional development.
Discussion
We described a strategy to employ the synbody platform to enable the creation of 1000 s of doses of a potential 
antibiotic or antiviral in a week. We first developed a 100-peptide microarray, with peptides that would bind one 
or more pathogens. To do this we screened 21 diverse bacteria and viruses on a 10,000 peptide microarray. Over 
1% of the peptides on the array bound multiple pathogens, with some lytic to bacteria, and these were chosen for 
further screening. These peptides were synthesized and assessed for binding the pathogen panel by ELISA-type 
binding and for in vitro toxicity to human cells. A library of 100 peptides were chosen, synthesized and purified 
on large scale. These peptides were printed on small microarrays and were the core for the rapid screening. A sys-
tem for rapidly synthesizing and screening synbodies was demonstrated. As a demonstration project synbodies 
Figure 5. Development of antiviral synbodies against A/California/07/2009 pdm09 H1N1, a model unknown 
virus. (A) Relative fluorescence (RFU) for each peptide from binding of pdm09 H1N1. Values represent 
mean ± s.e.m. for six replicate spots per peptide. Background binding was measured in empty spots (Bkgd.) and 
peptide hits had mean binding that was significantly higher (p < 0.01) while a negative control peptide (p94) 
did not. (B) Inhibition of pdm09 H1N1 hemagglutination by synbodies. Error bars represent the standard error 
from replicate assays. (C) Plaque reduction of pdm09 H1N1 infected MDCK cells with candidate synbodies. 
A neutralizing pdm09 H1N1 mAb was used as a positive control and three HAI inhibiting (p125-p125, 
p125-p149, p227-p227) and a non-HAI inhibiting synbody (p151-p151) were tested. Error bars represent the 
standard error from replicate assays.
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against influenza virus that is effective in vitro were produced and the same process was used to produce an 
antibiotic against S. epidermis in one week which inhibited growth at 6.25 µM.
We had previously demonstrated that synbodies could be developed with antibiotic activity18 and shown the 
value of using D amino acid-containing peptides19,20. The challenge we addressed here was whether the process 
could be done very quickly. The key was developing the 100-peptide microarray that was representative enough 
of broad pathogen-binding/lytic space. This allowed us to pre-stock large amounts of peptides for combinatorial 
production of the synbodies. Of note, the cost of synthesis of peptides has decreased notably and economies of 
scale enable the commercial production of numerous peptide therapeutics25. The second new feature was the 
development of a system for the rapid synthesis and screening of candidate synbodies. This required the opti-
mization of the conjugation chemistry. The third new aspect was the incorporation of rapid toxicity screening.
An underlying assumption of this approach was that pathogen surface space has enough redundancy that 100 
different peptides could cover its diversity. That this was true implies that pathogens as diverse as bacteria and 
viruses have overlapping chemical diversity. All the pathogens screened were infectious agents. It is possible that 
being a human pathogen and evolving against the human immune systems constrains the surface diversity of any 
pathogen. Analysis of the 100 peptide sequences did not reveal any obvious trends or common motifs that would 
suggest targeting a specific pathogen through homology with a natural receptor. Alternatively, the 100 peptides 
are predicted to lack secondary structure given the random amino acid distribution and length, and therefore 
could bind other targets with comparable affinity but through a different mechanism of action. We are currently 
investigating this further.
The demand on time did not allow us to incorporate one synbody related technology. We have shown that a 
candidate peptide could be greatly improved in affinity or refined in other selectable features16. This was done by 
making a matrix of single amino acid variants and screening them. The increase in affinity was simply additive 
for the variants. However, relative to this process the addition of this step would add at least 9 weeks (largely due 
to time to synthesis and the iterative nature of the optimization method) to the time required. This may be an 
acceptable addition in most circumstances of emergency but we wished to test the limits of the process in this 
demonstration.
Figure 6. Development of antibacterial synbodies against S. epidermidis. (A) S. epidermidis was labeled 
with CTO and AF647 and 106 CFU/mL S. epidermidis was screened against the 100-peptide microarray. 
(B) Synbodies were tested for S. epidermidis growth inhibition after 18-hour treatment at the indicated 
concentrations.
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As an example, we outline how this process as described might be applied to a situation like the 2014 Ebola 
outbreak in West Africa. The first step would be to apply intact Ebola virus to the 100-peptide array. This could be 
done using high titer inactivated blood or sera in a BSL2 facility. The virus binding to peptides would be detected 
using labeled anti-Ebola antibody with the total assay time of less than 1 day. This process would identify ~10 pep-
tides that would be used to create a panel of synbodies. Conjugation reactions of synbodies would be performed 
in parallel and proceed to completion within a few hours. Purification of synbodies is performed by HPLC in 
parallel and these synbodies could be screened for binding inactivated Ebola virus in a BSL2 facility. Cell toxicity 
and hemolysis screening could be done in parallel. Positive candidates would then have to be screened for inac-
tivation of virus in a cell-based assay that would require BSL4 containment. Two or more of the best candidates 
could then be synthesized from the large stocks and purified. Presumably, these synbodies could then be tested in 
animal models for safety and protection in challenge models.
This system will have several limitations. Though even dangerous pathogens can be screened in BSL2 facilities 
if killed, the activity screens would have to be conducted with live pathogen at higher containment. Screening 
with killed or viable viruses probably will not matter. However, a screen with killed bacteria would not discrim-
inate lytic peptides. In this case it may require attaching a bacterial killing element to the binding synbody. For 
example, we, and others, have explored using ligands to recruit existing antibodies to pathogens26–28. Finally, 
the synbodies as produced by this process would probably not be orally administrable unless further formu-
lated. However, they may be used by intravenous injection. Possibly the biggest concern for employing this sys-
tem is that the product is a peptide-based therapeutic. While antimicrobial peptides (AMPs) have a poor track 
record in producing clinical products29 antibiotics such as daptomycin, vancomycin, and colistin are peptidic. 
Additionally, the clinically approved HIV fusion inhibitor enfuvirtide is a 36-aa peptide with an elimination 
half-life of 3.8 hours30. There are many standard methods for improving the protease stability of peptide thera-
peutics, including the incorporation of D-amino acids19,20, and would be used in future implementations of the 
system.
We demonstrated a potential workflow to produce 1000 s of doses of an anti-infective. To produce enough 
product for a population-wide use would require substantial scaling in production of peptides and purification 
of the synbodies. However, even the focused, rapid use of an anti-infective could be useful. For example, in the 
Ebola outbreak, the protection of healthcare workers was a major concern and for the Zika outbreak the concern 
is for women who might become pregnant.
We consider synbody antibiotics and antivirals to have more similarity to antibody therapeutics than AMPs. 
Antibodies and serum therapy have been used as both antiviral and antibacterial treatments with a number of 
monoclonal and polyclonal antibodies approved31. Some have argued that antibodies should be revisited as a 
mode of treating infections, particularly in light of increased antibiotic resistance32. Clearly, cost would be a major 
concern for the broad use of antibodies. In this regard, synbodies may have an advantage in that they should be 
less expensive to chemically synthesize than biologically produced antibodies. A unique feature of the use of the 
peptide synbody scaffold is that the same platform can produce synbodies with direct antibiotic or antiviral activ-
ity and should be useful for primary and secondary infections.
In summary, we have demonstrated the feasibility of producing candidate antibiotics or antivirals in a very 
short time. With a scaled pre-investment, even a wider selection of peptide candidates could be used on the selec-
tion microarray and more doses of each candidate made. Some of the features demonstrated here, for example the 
rapid synthesis of a large number of synbody candidates, could also be used in standard approaches to therapeutic 
development. Alternatively, parallel advances in high density peptide microarray synthesis33–38 and rapid peptide 
synthesis39, could dramatically increase the diversity of the peptide screening and decrease time to synthesize the 
resulting hits. These emerging technologies could eliminate the need for library pre-synthesis and yet maintain 
the speed of the discovery platform, increasing the potential for this approach.
Methods
Peptide Microarrays. Glass microscope slides are coated with polyethylenimine prior to peptide printing 
in order to create a high density peptide surface in each feature18. Sulfosuccinimidyl 4-(N-maleimidomethyl)
cyclohexane-1-carboxylate (Sulfo-SMCC) is applied to the amine surface to activate the microarray prior to 
printing the peptides. The peptides are 20 amino acids long with a CSG linker on the N-terminus, with the 
N-terminal Cys functioning as the conjugation site to the peptide microarray. Cysteine is excluded from the 17aa 
variable region. The peptide sequences were generated from a random number generator, with minor amino acid 
biases. Peptides were synthesized by Sigma Custom Peptide (The Woodlands, TX) and used without purification. 
Peptides were diluted to 1 mg/mL in 25 μM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) pH 
7.3 + 10% acetonitrile (AcCN) prior to dispensing. Peptides were printed by Applied Microarray, Inc. (Tempe, 
AZ) using non-contact piezo printing in 90% humidity. Arrays were washed in 70% AcCN, 30% methanol 
(MeOH), then washed in water (ddH2O) for 1 hour prior to use.
Peptide Microarray Screening. Peptide microarrays were blocked with 600 μL blocking buffer [3% 
bovine serum albumin (BSA), 0.05% Tween20, 0.134 mg/ml Mercaptohexanol in 1x Tris buffered saline (TBS)] 
in a humidity chamber for 1 hour at room temperature. Microarrays were washed with washing buffer (1x 
TBS + 0.05% Tween20) followed by two washes with ddH2O. Virus solutions were prepared in dilution buffer 
(5 mg/mL BSA + protease inhibitor), applied to the peptide microarray, and incubated in Agilent microarray 
chambers for 1 hour at 37 °C. Microarrays were washed, probed with 250 μL of the appropriate detection antibody 
in Agilent microarray chambers for 1 hour at 37 °C, washed and probed with 250 μL of 5 nM AlexaFluor-647 con-
jugated secondary antibody for 1 hour at 37 °C. Arrays were washed, dried, and scanned on an Agilent Microarray 
Scanner. Each sample was run on duplicate arrays. Each primary antibody was screened in absence of pathogen 
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as a negative control. Data were analyzed with Microsoft Excel or JMP Pro 13. For bacteria binding we used our 
previously published method18.
Synbody Library Production. Synbodies were produced according to developed methods19–21. Synbody 
scaffolds were synthesized by Sigma Custom Peptide at 90% purity and used as before. Briefly, the peptide and the 
scaffold are separately dissolved in 30% AcCN. One equivalent of the scaffold is mixed with two equivalents of 
the peptide; the pH of the reaction mixture is adjusted to 6.5–7.0 with the addition of dilute 10% trimethylamine 
(TEA) in AcCN. The reaction incubates at room temperature and was monitored by HPLC and MALDI-MS. 
Synbodies are purified by HPLC, molecular weight confirmed by MALDI, and lyophilized prior to use.
Peptide ELISA Assay. Nunc MaxiSorp flat bottom 96 well ELISA plates were coated with 50 μL of 0.2 μg/
well of each pathogen in ELISA coating buffer and kept overnight at 4 °C. Plates were washed three times with 
1x phosphate buffered saline + 0.05% Tween20 (PBST) using a BioTek ELx405 plate washer followed by blocking 
with 100 μL 3% BSA in 1x PBST for 2 hours at 37 °C. Plates were washed and biotin labeled peptides added in dilu-
tion buffer [0.1% BSA + 1x PBST + 0.05% v/v Tween20] and incubated for 1 hour at 37 °C. Plates were washed, 
100 μL of 1:2000 streptavidin-Horseradish peroxidase (HRP) was added, and incubated for 1 hour at 37 °C. Plates 
were washed, 100 μL of 3,3′,5,5′-tetramethylbenzidine (TMB) (Thermo Scientific) was added, and incubated in 
the dark for 15 minutes at room temperature. The reaction was quenched with 100 μL of 0.5 M hydrochloric acid 
(HCl) and read immediately at 450 nm using a microplate reader (Spectra MAX 190, Molecular Devices, Inc.). 
Peptides that exhibited concentration dependent binding, were screened again at appropriate concentrations to 
confirm pathogen binding.
Measurement of Cytotoxic Potential of Peptides. HEK293 cells were washed in assay medium, diluted 
to the desired concentrations, and dispensed at 100 μL in a sterile 96-well tissue culture plate with 50,000 cells 
added in each well. The cells were incubated overnight (37 °C, 5% CO2, 90% humidity). In order to remove resid-
ual LDH activity from the cells, the overnight assay media was replaced with new media. Peptides were diluted to 
2 times their final concentration in assay media and dispensed at 200 μL in a separate 96-well plate. Peptides were 
then dispensed at 100 μL into duplicate or triplicate wells of the cell containing plate along with the appropriate 
controls and incubated for 24 hours (37 °C, 5% CO2, 90% humidity). Supernatant was carefully removed and 
transferred into an optically clear 96-well flat bottom microplate where freshly prepared LDH reaction mixture 
(Roche) was dispensed at 100 μL in each well and incubated for 30 min at 25 °C. To stop the reaction, 50 μL of 
stop solution was added to each well and the absorbance of the samples were measured using a microplate reader 
(Spectra MAX 190, Molecular Devices, Inc.). Cytotoxicity was calculated according to the manufacturer’s recom-
mendation and cell viability from replicate wells was calculated as 1 – cytotoxicity.
Hemagglutination Assay. Initial hemagglutination assays were done to determine the titer to be used for 
subsequent hemagglutination inhibition and were repeated for each new turkey red blood cell (tRBC) lot. Initially 
50 µL of 1x PBS solution was added to all wells to be used in a 96 plate. The initial titer for A/CA/7/2009 H1N1 
pdm09 (BEI Resources: NR-13663) was added in duplicate at concentrations of 1/50 in 50 µL. The virus was 
serially diluted in 2 fold dilutions across the plate. 50 µL of a solution of 0.5% tRBCs (Innovative Research cat no. 
IR1-110N) were added, and the plate was incubated at 30–60 minutes at room temperature. After incubation the 
plate was checked for hemagglutination. A positive hemagglutination result was determined by the appearance of 
a diffuse red color across the well. A negative result appeared as dots in the center of the round bottom plates. The 
HA titer was determined as the highest dilution factor to cause a positive hemagglutination result. This minimum 
HA concentration was labeled as 1 HAU unit. Subsequent testing of new lots of tRBC’s followed the same proce-
dure as above except with starting virus concentration of 1/25.
Hemagglutination Inhibition Assay. For the hemagglutination inhibition (HAI) assay, the viral titer pre-
viously determined was used. For the initial assay of candidate peptides 25 µL of PBS was added to all wells of 
a 96-well plate. For each peptide, 25 µL of 200 µM solution and 25 µL of PBS was added prior to serial dilution 
across the row in 2 fold dilutions. Twenty-five µL of a 1/100 dilution of pdm09 was added to all of the wells to 
achieve a concentration of 1 HAU. The plate was incubated for 30 minutes at room temperature. Then, 50 µL of 
0.5% tRBC’s were added and the plate was incubated for 30–60 minutes. The hemagglutination was then meas-
ured. The minimum inhibitory concentration for each peptide was defined as the highest concentration that 
produced a negative hemagglutination result. Subsequent assays were run as before starting with 25 µM or 50 µM 
of synbody that was 2-fold diluted across the row.
Plaque Reduction Neutralization Assay. Madin-Darby canine kidney cells (MDCK) were grown in 
6-well plates (1 × 106 cells/well). Then, pdm09 influenza (100 PFU) was incubated with serial dilutions (50 µM 
to 0.05 µM) of synbodies in minimal essential medium (MEM) (Gibco) for 1 hour at 37 °C. Mixtures were trans-
ferred onto MDCK cells in 6-well plates and incubated 1 hour at 37 °C with 5% CO2. After incubation, virus and 
synbody mixtures were removed and cells were overlaid with 0.3% agarose-MEM medium supplemented with 
1 μg/ml of TPCK-trypsin (Sigma). Infected MDCK cells were cultured for 2 days 37 °C at 5% CO2, fixed with 3% 
formaldehyde and stained with 1% crystal violet. Number of plaque forming unit was determined and percentage 
of plaque reduction was calculated based on the PFU produced by the virus without treatment. An anti-pdm09 
monoclonal antibody (serial dilutions from 1:100 to 1:25,600) and p151-p151 synbody were used as positive and 
negative controls. The monoclonal Anti-Influenza Virus antibody was obtained through BEI Resources, NIAID, 
NIH: Monoclonal Anti-Influenza Virus H1 Hemagglutinin (HA), A/California/04/2009 (H1N1) pdm09, Clone 
4F8 (produced in vitro), NR-42021. Assay was repeated, at least, three times independently and data are repre-
sented as ± SEM.
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MIC Assay. We determined bacterial growth inhibition using an adapted version of the broth microdilution 
method40 in which peptides or synbodies were diluted with 1x PBS and added in triplicate wells to bacterial 
suspensions of ~106 CFU/mL in Mueller-Hinton Broth (MHB) in 96-well polypropylene plates18,19. Plates were 
incubated with shaking overnight at 37 °C and the OD600 was measured using a microplate reader. Visible growth 
was defined as OD < 0.08 or < 10% growth relative to the untreated control. Assays were performed in duplicate.
Hemolytic Assay. Red blood cell toxicity was measured using a previously published hemolytic assay18. 
These experiments followed an animal use protocol (1099 R) that was reviewed and approved by the Arizona State 
University Institutional Animal Care and Use Committee an all experiments were performed in accordance with 
relevant guidelines and regulations. Briefly, blood from female BALB/C mice was collected via terminal bleed, 
centrifuged at 300 g for 5 minutes, the sera was discarded, red blood cells were rinsed three times with 1xPBS (v/v 
– RBC: PBS), and centrifuged at 900 g for 15 minutes. Washed RBCs were diluted to 4% in 1x PBS and 50 μL were 
dispensed into triplicate wells of a 96-well plate. Synbody samples (50 μL), ddH2O positive controls, or 1x PBS 
negative controls were added to each well and the plate was allowed to incubate at 37 °C for 1 hour. The plate was 
centrifuged at 1000 g for 5 minutes and 90 μL of the supernatant from each well was removed and dispensed into 
a new 96 well titer plate. The absorbance at 414 nm was measured and the percent hemolysis was calculated using 
the following formula: percent hemolysis = [Avg. Sample Absorbance/Avg. Control Absorbance] * 100. Assays 
were performed in duplicate.
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